Literature DB >> 23292208

Factors predicting the Montreal cognitive assessment (MoCA) applicability and performances in a stroke unit.

Marco Pasi1, Emilia Salvadori, Anna Poggesi, Domenico Inzitari, Leonardo Pantoni.   

Abstract

The evaluation of cognitive status is not routine in the acute stroke setting. We aimed to investigate feasibility, applicability, and performances of the Montreal cognitive assessment (MoCA) in acute stroke patients. Consecutive stroke patients (ischemic or hemorrhagic) admitted to one stroke unit were evaluated 5-9 days after stroke with MoCA (score range: 0-30; higher scores indicate better cognitive performance). Pre-morbid functional and cognitive status was assessed by a structured interview to caregivers. Neuroimaging data regarding index stroke and pre-existing lesions were collected. From December 2009 to December 2010, out of 207 patients with stroke, 137 (66%) were enrolled [mean age 69.2 ± 14.8 years; males 62%; mean National Institute of Health and Stroke Scale (NIHSS) score 5.9 ± 7.9]. The most common reason for non-enrolment was unfitting the time window inclusion criteria. MoCA was entirely applicable to 113/137 (82.5%) patients and the mean score was 17.8 ± 7.1. Multivariate analyses showed that non-applicability was associated with higher NIHSS scores [OR (95% CI) = 1.4 (1.2-1.7) for each point], left sided lesions [OR (95% CI) = 18.8 (2.3-155.2)], and worse pre-morbid functional status [OR (95% CI) = 0.7 (0.6-0.9) for each point of the instrumental activity of daily living scale]. Factors influencing MoCA performance were low education (β = 0.264, p < 0.01), higher NIHSS scores (β = -0.277, p < 0.01) and worse pre-morbid functional status (β = 0.504, p < 0.001). MoCA administration is feasible in acute patients with mild-to-moderate stroke, with lesion location, stroke severity, and pre-morbid functional status as major determinants of its applicability and performance. MoCA seems to reveal some degree of cognitive deficit even in patients with mild stroke.

Entities:  

Mesh:

Year:  2013        PMID: 23292208     DOI: 10.1007/s00415-012-6819-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

2.  Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientific statement from the American Heart Association.

Authors:  Elaine L Miller; Laura Murray; Lorie Richards; Richard D Zorowitz; Tamilyn Bakas; Patricia Clark; Sandra A Billinger
Journal:  Stroke       Date:  2010-09-02       Impact factor: 7.914

3.  Brief assessment of cognitive impairment in patients with stroke.

Authors:  V E Hajek; D L Rutman; H Scher
Journal:  Arch Phys Med Rehabil       Date:  1989-02       Impact factor: 3.966

4.  Detecting cognitive impairment in clients with mild stroke or transient ischemic attack attending a stroke prevention clinic.

Authors:  Gail MacKenzie; Linda Gould; Sandra Ireland; Kathryn LeBlanc; Demetrios Sahlas
Journal:  Can J Neurosci Nurs       Date:  2011

Review 5.  Poststroke dementia.

Authors:  H Hénon; F Pasquier; D Leys
Journal:  Cerebrovasc Dis       Date:  2006-04-26       Impact factor: 2.762

6.  Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study.

Authors:  Sarah T Pendlebury; Fiona C Cuthbertson; Sarah J V Welch; Ziyah Mehta; Peter M Rothwell
Journal:  Stroke       Date:  2010-04-08       Impact factor: 7.914

7.  The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome.

Authors:  Joan Toglia; Kerri A Fitzgerald; Michael W O'Dell; Andrea R Mastrogiovanni; C David Lin
Journal:  Arch Phys Med Rehabil       Date:  2011-05       Impact factor: 3.966

Review 8.  Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.

Authors:  Sarah T Pendlebury; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2009-09-24       Impact factor: 44.182

9.  Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology.

Authors:  Leonardo Pantoni; Anna Maria Basile; Giovanni Pracucci; Kjell Asplund; Julien Bogousslavsky; Hugues Chabriat; Timo Erkinjuntti; Franz Fazekas; José M Ferro; Michael Hennerici; John O'brien; Philip Scheltens; Marieke C Visser; Lars-Olof Wahlund; Gunhild Waldemar; Anders Wallin; Domenico Inzitari
Journal:  Neuroepidemiology       Date:  2005       Impact factor: 3.282

10.  Grading white matter lesions on CT and MRI: a simple scale.

Authors:  J C van Swieten; A Hijdra; P J Koudstaal; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

View more
  13 in total

1.  Italian normative data for a stroke specific cognitive screening tool: the Oxford Cognitive Screen (OCS).

Authors:  M Mancuso; V Varalta; L Sardella; D Capitani; P Zoccolotti; G Antonucci
Journal:  Neurol Sci       Date:  2016-07-09       Impact factor: 3.307

2.  Cognitive reserve impacts on disability and cognitive deficits in acute stroke.

Authors:  Roza M Umarova; Christoph Sperber; Christoph P Kaller; Charlotte S M Schmidt; Horst Urbach; Stefan Klöppel; Cornelius Weiller; Hans-Otto Karnath
Journal:  J Neurol       Date:  2019-06-28       Impact factor: 4.849

3.  Optimal MoCA cutoffs for detecting biologically-defined patients with MCI and early dementia.

Authors:  Ciro Rosario Ilardi; Alina Menichelli; Marco Michelutti; Tatiana Cattaruzza; Paolo Manganotti
Journal:  Neurol Sci       Date:  2022-09-28       Impact factor: 3.830

4.  Predictive value of MoCA in the acute phase of stroke on the diagnosis of mid-term cognitive impairment.

Authors:  Emilia Salvadori; Marco Pasi; Anna Poggesi; Guido Chiti; Domenico Inzitari; Leonardo Pantoni
Journal:  J Neurol       Date:  2013-05-29       Impact factor: 4.849

5.  Methodological Factors in Determining Risk of Dementia After Transient Ischemic Attack and Stroke: (III) Applicability of Cognitive Tests.

Authors:  Sarah T Pendlebury; Stephen P Klaus; Ross J Thomson; Ziyah Mehta; Rose M Wharton; Peter M Rothwell
Journal:  Stroke       Date:  2015-10-13       Impact factor: 7.914

6.  Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3-6 months after mild stroke and transient ischaemic attack: an observational study.

Authors:  Yanhong Dong; Melissa Jane Slavin; Bernard Poon-Lap Chan; Narayanaswamy Venketasubramanian; Vijay Kumar Sharma; John D Crawford; Simon Lowes Collinson; Perminder Sachdev; Christopher Li-Hsian Chen
Journal:  BMJ Open       Date:  2013-09-03       Impact factor: 2.692

7.  A robot-based behavioural task to quantify impairments in rapid motor decisions and actions after stroke.

Authors:  Teige C Bourke; Catherine R Lowrey; Sean P Dukelow; Stephen D Bagg; Kathleen E Norman; Stephen H Scott
Journal:  J Neuroeng Rehabil       Date:  2016-10-10       Impact factor: 4.262

8.  Feasibility of Cognitive Functions Screened With the Montreal Cognitive Assessment in Determining ADL Dependence Early After Stroke.

Authors:  Tamar Abzhandadze; Lena Rafsten; Åsa Lundgren-Nilsson; Katharina S Sunnerhagen
Journal:  Front Neurol       Date:  2018-08-27       Impact factor: 4.003

9.  High levels of plasma fibrinogen are related to post-stroke cognitive impairment.

Authors:  Yuntao Liu; Huijun Chen; Kai Zhao; Weilei He; Shasha Lin; Jincai He
Journal:  Brain Behav       Date:  2019-09-02       Impact factor: 2.708

10.  Who Is Classified as Untestable on Brief Cognitive Screens in an Acute Stroke Setting?

Authors:  Emma Elliott; Bogna A Drozdowska; Martin Taylor-Rowan; Robert C Shaw; Gillian Cuthbertson; Terence J Quinn
Journal:  Diagnostics (Basel)       Date:  2019-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.